Multiplex Assay Kit for Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay)

Ng; NEUG; Protein Kinase C Substrate RC3

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 93-101 97
EDTA plasma(n=5) 90-104 97
heparin plasma(n=5) 78-93 83

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 99-105% 95-102% 79-94% 85-105%
EDTA plasma(n=5) 82-103% 79-104% 78-97% 84-95%
heparin plasma(n=5) 98-105% 80-103% 87-94% 79-95%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:NRGN) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 50μL standard or sample to each well,
    add 10μL magnetic beads,and 50μL Detection Reagent A,incubate 60min at 37°C on shaker;
3. Wash plate on magnetic frame for three times;
4. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
5. Wash plate on magnetic frame for three times;
6. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile Pubmed:27408937
Annals of Clinical and Translational Neurology Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging Pubmed:27231710
The FASEB Journal Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease pubmed:27601437
Journal of Alzheimer's Disease Growth Hormone-Releasing Hormone Administration in Mild Cognitive Impairment and Its Impact on Neuronal Exosome Biomarkers of Dementia Doi: 10.3233/JAD-180302
SYNAPTIC PROTEIN BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
Am J Emerg Med The diagnostic value of neurogranin in patients with carbon monoxide poisoning: Can it show early neurological damage? 34388687
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA404Hu01 Recombinant Neurogranin (NRGN) Positive Control; Immunogen; SDS-PAGE; WB.
PAA404Hu01 Polyclonal Antibody to Neurogranin (NRGN) WB; IHC; ICC; IP.
FAA404Hu01 Anti-Neurogranin (NRGN) Polyclonal Antibody Flow cytometry.
MAA404Hu27 Monoclonal Antibody to Neurogranin (NRGN) WB; IHC; ICC; IP.
MAA404Hu29 Monoclonal Antibody to Neurogranin (NRGN) WB; IHC; ICC; IP.
MAA404Hu23 Monoclonal Antibody to Neurogranin (NRGN) WB,IHC
MAA404Hu24 Monoclonal Antibody to Neurogranin (NRGN) WB; IHC; ICC; IP.
MAA404Hu25 Monoclonal Antibody to Neurogranin (NRGN) WB; IHC; ICC; IP.
MAA404Hu22 Monoclonal Antibody to Neurogranin (NRGN) WB,IHC
MAA404Hu21 Monoclonal Antibody to Neurogranin (NRGN) WB; IHC
FAA404Hu02 Anti-Neurogranin (NRGN) Monoclonal Antibody Flow cytometry.
FAA404Hu04 Anti-Neurogranin (NRGN) Monoclonal Antibody Flow cytometry.
FAA404Hu06 Anti-Neurogranin (NRGN) Monoclonal Antibody Flow cytometry.
CEA404Hu ELISA Kit for Neurogranin (NRGN) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA404Hu Multiplex Assay Kit for Neurogranin (NRGN) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.